Cas no 17745-32-3 (methyl 5-oxoheptanoate)
methyl 5-oxoheptanoate Chemical and Physical Properties
Names and Identifiers
-
- Heptanoic acid, 5-oxo-, methyl ester
- 5-Ketoenanthic acid methyl ester
- methyl 5-oxoheptanoate
- 5-Oxoheptanoic acid methyl ester
- 17745-32-3
- MFCD07780262
- methyl5-oxoheptanoate
- AKOS006285908
- HIMIBFCIVOXHAY-UHFFFAOYSA-N
- EN300-1710045
- DA-09192
- NS-01229
- SCHEMBL8187268
-
- MDL: MFCD07780262
- Inchi: 1S/C8H14O3/c1-3-7(9)5-4-6-8(10)11-2/h3-6H2,1-2H3
- InChI Key: HIMIBFCIVOXHAY-UHFFFAOYSA-N
- SMILES: O=C(CC)CCCC(=O)OC
Computed Properties
- Exact Mass: 158.09432
- Monoisotopic Mass: 158.094294304g/mol
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 0
- Hydrogen Bond Acceptor Count: 3
- Heavy Atom Count: 11
- Rotatable Bond Count: 6
- Complexity: 140
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- XLogP3: 0.5
- Topological Polar Surface Area: 43.4?2
Experimental Properties
- PSA: 43.37
methyl 5-oxoheptanoate Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| TRC | B498173-10mg |
methyl 5-oxoheptanoate |
17745-32-3 | 10mg |
$ 50.00 | 2022-06-07 | ||
| TRC | B498173-50mg |
methyl 5-oxoheptanoate |
17745-32-3 | 50mg |
$ 210.00 | 2022-06-07 | ||
| TRC | B498173-100mg |
methyl 5-oxoheptanoate |
17745-32-3 | 100mg |
$ 295.00 | 2022-06-07 | ||
| Enamine | EN300-1710045-0.05g |
methyl 5-oxoheptanoate |
17745-32-3 | 95% | 0.05g |
$84.0 | 2023-09-20 | |
| Enamine | EN300-1710045-0.1g |
methyl 5-oxoheptanoate |
17745-32-3 | 95% | 0.1g |
$124.0 | 2023-09-20 | |
| Enamine | EN300-1710045-0.25g |
methyl 5-oxoheptanoate |
17745-32-3 | 95% | 0.25g |
$178.0 | 2023-09-20 | |
| Enamine | EN300-1710045-0.5g |
methyl 5-oxoheptanoate |
17745-32-3 | 95% | 0.5g |
$331.0 | 2023-09-20 | |
| Enamine | EN300-1710045-1.0g |
methyl 5-oxoheptanoate |
17745-32-3 | 95% | 1g |
$442.0 | 2023-06-04 | |
| Enamine | EN300-1710045-2.5g |
methyl 5-oxoheptanoate |
17745-32-3 | 95% | 2.5g |
$867.0 | 2023-09-20 | |
| Enamine | EN300-1710045-5.0g |
methyl 5-oxoheptanoate |
17745-32-3 | 95% | 5g |
$1280.0 | 2023-06-04 |
methyl 5-oxoheptanoate Related Literature
-
1. An autonomous self-optimizing flow machine for the synthesis of pyridine–oxazoline (PyOX) ligands?Eric Wimmer,Daniel Cortés-Borda,Solène Brochard,Elvina Barré,Charlotte Truchet,Fran?ois-Xavier Felpin React. Chem. Eng., 2019,4, 1608-1615
-
Kui Wu,Zhihua Yang,Shilie Pan Dalton Trans., 2015,44, 19856-19864
-
Bidyut Kumar Kundu,Rinky Singh,Ritudhwaj Tiwari,Debasis Nayak New J. Chem., 2019,43, 4867-4877
-
Robert J. Meagher,Anson V. Hatch,Ronald F. Renzi,Anup K. Singh Lab Chip, 2008,8, 2046-2053
Additional information on methyl 5-oxoheptanoate
Recent Advances in the Application of Methyl 5-Oxoheptanoate (CAS: 17745-32-3) in Chemical Biology and Pharmaceutical Research
Methyl 5-oxoheptanoate (CAS: 17745-32-3) is a key intermediate in organic synthesis and pharmaceutical research, known for its versatile applications in the production of bioactive compounds and drug candidates. Recent studies have highlighted its role in the synthesis of novel therapeutic agents, particularly in the fields of anti-inflammatory, antimicrobial, and anticancer research. This research brief aims to provide an overview of the latest advancements involving methyl 5-oxoheptanoate, focusing on its chemical properties, synthetic methodologies, and biological activities.
One of the most significant developments in the use of methyl 5-oxoheptanoate is its incorporation into the synthesis of prostaglandin analogs. Prostaglandins play a crucial role in various physiological processes, and their synthetic analogs have shown promise in treating conditions such as glaucoma and cardiovascular diseases. Researchers have optimized the catalytic processes to enhance the yield and purity of methyl 5-oxoheptanoate-derived prostaglandin intermediates, thereby improving the scalability of these compounds for clinical applications.
In addition to its role in prostaglandin synthesis, methyl 5-oxoheptanoate has been investigated as a precursor for the development of antimicrobial agents. A recent study published in the Journal of Medicinal Chemistry demonstrated that derivatives of methyl 5-oxoheptanoate exhibit potent activity against multidrug-resistant bacterial strains. The study utilized computational modeling and in vitro assays to identify the structural features responsible for the enhanced antimicrobial efficacy, paving the way for the design of next-generation antibiotics.
Another area of interest is the application of methyl 5-oxoheptanoate in cancer research. Scientists have explored its potential as a building block for the synthesis of histone deacetylase (HDAC) inhibitors, which are emerging as promising anticancer agents. A 2023 study in Bioorganic & Medicinal Chemistry Letters reported the successful synthesis of a series of HDAC inhibitors using methyl 5-oxoheptanoate as a key intermediate. These inhibitors demonstrated significant antiproliferative effects against various cancer cell lines, with minimal toxicity to normal cells.
Furthermore, advancements in green chemistry have enabled the environmentally friendly production of methyl 5-oxoheptanoate. Researchers have developed biocatalytic methods using engineered enzymes to synthesize the compound with high enantioselectivity and reduced waste generation. These sustainable approaches align with the growing demand for eco-friendly pharmaceutical manufacturing processes and have been well-received by the scientific community.
In conclusion, methyl 5-oxoheptanoate (CAS: 17745-32-3) continues to be a valuable compound in chemical biology and pharmaceutical research. Its diverse applications, from prostaglandin analogs to antimicrobial and anticancer agents, underscore its importance in drug discovery and development. Future research is expected to further explore its potential, particularly in the context of personalized medicine and targeted therapies. The ongoing optimization of synthetic and biocatalytic methods will likely enhance its accessibility and utility in the pharmaceutical industry.